(Q33208591)

English

Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

prostate cancer

1 reference

based on heuristic

inferred from title

object named as

T Demkow

8

0 references

author name string

R P Abratt

1

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

D Brune

2

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

M-A Dimopoulos

3

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

J Kliment

4

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

J Breza

5

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

F P Selvaggi

6

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

P Beuzeboc

7

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

S Oudard

9

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

publication date

1 November 2004

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

1613-1621

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

Hormone-refractory (D3) prostate cancer: refining the concept.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH429

21 January 2018

Management of Hormone-Sensitive and Hormone-Refractory Metastatic Prostate Cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH429

21 January 2018

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH429

21 January 2018

Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress?

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH429

21 January 2018

Phase II study of vinorelbine in patients with androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH429

21 January 2018

Vinorelbine in androgen-independent metastatic prostatic carcinoma--a phase II study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH429

21 January 2018

Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH429

21 January 2018

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH429

21 January 2018

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH429

21 January 2018

Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH429

21 January 2018

The Measurement of Observer Agreement for Categorical Data

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH429

21 January 2018

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH429

21 January 2018

Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH429

21 January 2018

Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH429

21 January 2018

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH429

21 January 2018

Epothilones: mechanism of action and biologic activity

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH429

21 January 2018

A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH429

21 January 2018

Identifiers

10.1093/ANNONC/MDH429

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33208591&oldid=1966956490"